Aspira Women's Health Inc. SEC filings AWHL
Aspira Women's Health Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Aug 12, 2011. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jul 15, 2026 (material agreement, new debt). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Jun 22, 2026 | — |
| NT 10-K | Filing | Apr 1, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Jan 9, 2026 | — |
| CORRESP | Letter to the SEC | Jan 7, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2026 | — |
| EFFECT | Filing | Nov 21, 2025 | — |
| CORRESP | Letter to the SEC | Nov 19, 2025 | — |
| D | Filing | Sep 18, 2025 | — |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| EFFECT | Filing | May 7, 2025 | — |
| CORRESP | Letter to the SEC | May 6, 2025 | — |
| CORRESP | Letter to the SEC | May 6, 2025 | — |
| CORRESP | Letter to the SEC | Apr 30, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2025 | — |
| DEFR14A | Filing | Apr 22, 2025 | — |
| D | Filing | Mar 20, 2025 | — |
| RW | Filing | Feb 13, 2025 | — |
| NT 10-Q | Filing | Nov 14, 2024 | Sep 30, 2024 |
| EFFECT | Filing | Sep 3, 2024 | — |
| CORRESP | Letter to the SEC | Aug 29, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2024 | — |
| EFFECT | Filing | Jul 24, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 22, 2024 | — |
| D | Filing | Jul 12, 2024 | — |
| EFFECT | Filing | Apr 25, 2024 | — |
| CORRESP | Letter to the SEC | Apr 24, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2024 | — |
| EFFECT | Filing | Apr 11, 2024 | — |
| CORRESP | Letter to the SEC | Apr 10, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2024 | — |
| D | Filing | Feb 7, 2024 | — |
| PRER14A | Filing | Dec 28, 2022 | — |
| DEFR14A | Filing | Jun 7, 2022 | — |
| EFFECT | Filing | Jan 28, 2021 | — |
| CORRESP | Letter to the SEC | Jan 26, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 25, 2021 | — |
| EFFECT | Filing | Sep 30, 2020 | — |
| CORRESP | Letter to the SEC | Sep 25, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2020 | — |
| D | Filing | Jul 15, 2020 | — |
| NT 10-K | Filing | Mar 31, 2020 | Dec 31, 2019 |
| EFFECT | Filing | Nov 7, 2017 | — |
| CORRESP | Letter to the SEC | Nov 3, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2017 | — |
| CORRESP | Letter to the SEC | Jul 25, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2017 | — |
| EFFECT | Filing | May 4, 2017 | — |
| CORRESP | Letter to the SEC | May 1, 2017 | — |
| CT ORDER | Filing | Jun 25, 2015 | — |
| EFFECT | Filing | May 11, 2015 | — |
| CORRESP | Letter to the SEC | May 11, 2015 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2015 | — |
| EFFECT | Filing | Oct 2, 2014 | — |
| EFFECT | Filing | Aug 7, 2013 | — |
| D | Filing | May 24, 2013 | — |
| DFAN14A | Filing | Mar 18, 2013 | — |
| DFAN14A | Form dfan14a | Mar 11, 2013 | — |
| DFAN14A | Form dfan14a | Feb 26, 2013 | — |
| DFAN14A | Form dfan14a | Feb 21, 2013 | — |
| DFAN14A | Form dfan14a | Feb 1, 2013 | — |
| DEFN14A | Form defn14a | Jan 29, 2013 | Jan 29, 2013 |
| PRRN14A | Form prrn14a | Jan 28, 2013 | — |
| CORRESP | Letter to the SEC | Jan 25, 2013 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2013 | — |
| PRER14A | Amendment no. 3 to preliminary proxy statement | Jan 18, 2013 | — |
| DFAN14A | Form dfan14a | Jan 10, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2012 | — |
| PREN14A | Form pren14a | Dec 12, 2012 | Dec 12, 2012 |
| UPLOAD | Letter from the SEC | Nov 20, 2012 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2012 | — |
| DFAN14A | Form dfan14a | Nov 16, 2012 | — |
| DFAN14A | Schedule 14a | Nov 13, 2012 | — |
| DFAN14A | Form dfan14a | Oct 22, 2012 | — |
| DFAN14A | Form dfan14a | Oct 16, 2012 | — |
| UPLOAD | Letter from the SEC | May 29, 2012 | — |
| CORRESP | Letter to the SEC | May 25, 2012 | — |
| PRRN14A | Amendment no. 4 | May 23, 2012 | — |
| UPLOAD | Letter from the SEC | May 22, 2012 | — |
| UPLOAD | Letter from the SEC | May 22, 2012 | — |
| PRRN14A | Form prrn14a | May 21, 2012 | — |
| PRER14A | Amendment no. 2 to the preliminary proxy statement | May 17, 2012 | — |
| PRER14A | Amendment no. 1 to the preliminary proxy statement | May 9, 2012 | — |
| PRRN14A | Form prrn14a | May 8, 2012 | — |
| UPLOAD | Letter from the SEC | May 8, 2012 | — |
| PRRN14A | Filing | May 4, 2012 | — |
| UPLOAD | Letter from the SEC | May 3, 2012 | — |
| UPLOAD | Letter from the SEC | May 2, 2012 | — |
| PREC14A | Preliminary proxy statement | Apr 25, 2012 | — |
| PREN14A | Preliminary proxy statement form pren 14a | Apr 20, 2012 | Apr 20, 2012 |
| CORRESP | Letter to the SEC | Mar 15, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2012 | — |
| UPLOAD | Letter from the SEC | Mar 2, 2012 | — |
| DFAN14A | Form dfan14a | Feb 29, 2012 | — |
| CT ORDER | Filing | Feb 8, 2012 | — |
Showing 96 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- AWHL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 926617
- Former names
- VERMILLION, INC. (until Jun 10, 2020); CIPHERGEN BIOSYSTEMS INC (until Aug 17, 2007)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.